Multiple studies have confirmed that declining levels of IGF-1 play a key role in the negative effects associated with the aging process, including a decrease in lean muscle mass and an increase in adipose (fat) tissue. One particular study conducted on 21 healthy men aged 61 to 81 years only provides further support for the notion that low IGF-1 levels in the body are strongly correlated with an increase in aging’s adverse effects.
In the study, the men were divided into two groups; one group received IGF-1 treatment three times weekly for six months while the control group received no treatment. By the end of the study, the effects on the group that received treatment were as pronounced as they were convincing. This group saw an average increase in lean muscle mass of 8.8% along with a 14.4% decrease in adipose tissue. Additionally, the group receiving treatment experienced an average increase of 1.6% in lumbar vertebral bone density along with a 7.1% average increase in skin thickness (thinning of the skin and certain bones is a significant effect of the aging process). Conversely, the control group receiving no treatment saw no change in muscle mass, adiposity, bone density, or skin thickness.
Studies such as this abound and only further reinforce the critical role IGF-1 plays in the body. Importantly, IGF-1 LR3 is considered to be 2-3 times more efficacious than unaltered IGF-1 in achieving these effects.
It is widely acknowledged that IGF1 LR3 is a powerful stimulator of muscle growth. Still, many are unaware of how IGF-1 LR3 exerts this effect on muscle tissue. While IGF-1 LR3 supports the growth and retention of existing muscle tissue, it also promotes the growth of new muscle cells and fibers. The ability of IGF-1 LR3 to additionally stimulate muscle cell proliferation underlies its potent anabolic nature and differentiates it from other muscle-building agents.
When an individual experiences certain muscular stimulation such as that caused by weight training, the body’s response involves a process called hypertrophy, which is an increase in the size of muscle cells already in existence. Importantly, this process affects only existing muscle cells. That is, only those muscle cells currently existing in the body increase in size; new muscle cells and fibers are not created. Indeed, the adult body has only a fixed number of muscle cells that may grow in this manner. However, studies have demonstrated that administration of IGF-1 LR3, also known as Long R3 IGF-1, in study subjects results in an increase in both the size of existing muscle cells as well as the development of new muscle cells (hyperplasia) and growth of new muscle fibers (mitogenesis). Studies have shown that muscular growth increases dramatically in the presence of IGF-1 LR3 administration, and these newly developed muscle cells increase in both size and density. Clinical research has established that IGF-1 LR3 is largely unique among other anabolic agents in its ability to promote hyperplasia and mitogenesis, adding yet another dimension to its remarkable list of effects.
In the study, the men were divided into two groups; one group received IGF-1 treatment three times weekly for six months while the control group received no treatment. By the end of the study, the effects on the group that received treatment were as pronounced as they were convincing. This group saw an average increase in lean muscle mass of 8.8% along with a 14.4% decrease in adipose tissue. Additionally, the group receiving treatment experienced an average increase of 1.6% in lumbar vertebral bone density along with a 7.1% average increase in skin thickness (thinning of the skin and certain bones is a significant effect of the aging process). Conversely, the control group receiving no treatment saw no change in muscle mass, adiposity, bone density, or skin thickness.
Studies such as this abound and only further reinforce the critical role IGF-1 plays in the body. Importantly, IGF-1 LR3 is considered to be 2-3 times more efficacious than unaltered IGF-1 in achieving these effects.
It is widely acknowledged that IGF1 LR3 is a powerful stimulator of muscle growth. Still, many are unaware of how IGF-1 LR3 exerts this effect on muscle tissue. While IGF-1 LR3 supports the growth and retention of existing muscle tissue, it also promotes the growth of new muscle cells and fibers. The ability of IGF-1 LR3 to additionally stimulate muscle cell proliferation underlies its potent anabolic nature and differentiates it from other muscle-building agents.
When an individual experiences certain muscular stimulation such as that caused by weight training, the body’s response involves a process called hypertrophy, which is an increase in the size of muscle cells already in existence. Importantly, this process affects only existing muscle cells. That is, only those muscle cells currently existing in the body increase in size; new muscle cells and fibers are not created. Indeed, the adult body has only a fixed number of muscle cells that may grow in this manner. However, studies have demonstrated that administration of IGF-1 LR3, also known as Long R3 IGF-1, in study subjects results in an increase in both the size of existing muscle cells as well as the development of new muscle cells (hyperplasia) and growth of new muscle fibers (mitogenesis). Studies have shown that muscular growth increases dramatically in the presence of IGF-1 LR3 administration, and these newly developed muscle cells increase in both size and density. Clinical research has established that IGF-1 LR3 is largely unique among other anabolic agents in its ability to promote hyperplasia and mitogenesis, adding yet another dimension to its remarkable list of effects.
